Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Herbal Preparation and Glucose Homeostasis (Herbie)

14. februar 2014 oppdatert av: Wageningen University

Rationale: The incidence of obesity and type 2 diabetes (T2D) is increasing rapidly and accounts for a considerable part of health care costs. Herbal supplements are used in many cultures for the prevention and treatment of many different conditions. Due to lack of scientific proof, the application in western cultures are minimal. Animal studies have shown that many constituents of such herbal supplements may have beneficial effects on several important parameters known to be affected in T2D. Still, no scientific proof in humans is available. We therefore aim to investigate the effect of 4-week herbal supplementation on glucose metabolism, lipid metabolism, vascular function and inflammation in subjects with increased fasting glucose levels or a decreased glucose tolerance.

Objective: The primary objectives are to investigate if 4-week herbal supplementation in subjects with increased fasting glucose levels or a decreased glucose tolerance has a positive effect on blood glucose levels and glucose tolerance. The secondary objectives are to investigate if 4-week herbal supplementation in subjects with increased fasting glucose levels or a decreased glucose tolerance has a positive effect on triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) levels, inflammation, adipose tissue and white blood cell gene-expression and AIX both fasted and during an OGTT test.

Study design: This study is a randomized, double-blind, placebo controlled cross-over trial in which two different treatments will be evaluated e.g. an intervention with the herbal mixture and a placebo. Each person will obtain both treatments in random order for four weeks with a wash out period of four weeks in-between. Fasting blood samples will be collected and subjects will receive a OGTT, paralleled by a PWA before and after 4-week supplementation.

Furthermore, after 4-week supplement intake we will collect a urine sample and collect an adipose tissue biopsy. The whole trial will last three months.

Study population: 26 overweight males and females 50-75yrs old with an increased fasting glucose or with an impaired glucose tolerance.

Intervention: Two intervention periods of 4-weeks in which participants will take three times a day a supplement of 500mg herbal or placebo.

Main study parameters/endpoints: Fasting blood glucose levels, glucose tolerance as determined by an oral glucose tolerance test (OGTT), AIX, triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) levels, PWA, adipose tissue an white blood cell gene expression and markers of inflammation .

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Subjects that will participate in the study will invest a total of 16.5 hours. Blood collection by vena punctures/insertion of the venflon and the collection of an adipose tissue biopsy can occasionally cause a local hematoma or bruise and some participants may report pain or discomfort. The herbal supplements contain small amounts St. John's wort, which may affect the function of liver enzymes. We will therefore monitor liver function parameters during the supplementation period. Furthermore, subjects are excluded if they use medication known to be affected by St. John's wort. Participant will donate 284ml of blood, dispersed over 12 weeks.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

22

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Gelderland
      • Wageningen, Gelderland, Nederland, 6703 HD
        • Wageningen University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

50 år til 70 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Males and postmenopausal females For females: menstrual cycle absent for more than 1 year
  • age 50-70yrs
  • BMI >27 kg/m2
  • Increased fasting glucose or an impaired glucose tolerance (two-hour glucose levels >7.8 mmol/L on the 75-g oral glucose tolerance test or fasting glucose >6.1mmol/L).

Exclusion Criteria:

  • Systolic blood pressure >160mmHg and diastolic blood pressure> 100mmHg
  • Tobacco smoker
  • Received inoculations within 2 months of starting the study or planned during the study
  • Donated or intend to donate blood from 2 months before the study till months after the study.
  • Unstable body weight (weight gain or loss >5kg in the past three months)
  • Diagnosed with any long-term medical condition (e.g., diabetes, haemophilia, CVD, anemia, gastrointestinal disease, renal failure, thyroid disorders, cancer, HIV, hepatitis C)
  • The use of the following medicine: medicine interfering with St Johns Worth such as, inhibitors of the immune system (ciclosporine, tacrolimus, everolimus, temsirolimus and sirolimus), coumarine type anticoagulant medicine (acenocoumarol and fenprocoumon), anti-epileptica (fenobarbital and fenytoïne), theophylline, atorvastatine, simvastatine, digoxine, kinidine, voriconazol, proton pump inhibitors (omeprazole and esomeprazole) and all anti-depressives ( incl. MAO inhibitors and SSRI's).
  • Abuse of drugs/alcohol
  • If the participant don't want to sign the informed consent
  • If the participant don't want to be informed about unexpected findings during the screening or study
  • Participation in another biomedical study
  • Additional exclusion criteria for females:

Current use of contraceptives containing hormones Current use of hormone replacement therapy

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: herbal supplements
500mg, 3 per day, 4weeks
Placebo komparator: placebo
500mg, 3 per day, 4 weeks

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
change in glucose tolerance
Tidsramme: baseline and after 4-week supplementation
by oral glucose tolerance test (OGTT)
baseline and after 4-week supplementation

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
change in insulin
Tidsramme: baseline and after 4-week supplementation
baseline and after 4-week supplementation
change in TAG
Tidsramme: baseline and after 4 week supplementation
baseline and after 4 week supplementation
change in HbA1c
Tidsramme: baseline and after 4 week supplementation
glycosylated haemoglobin
baseline and after 4 week supplementation
change in FFA
Tidsramme: baseline and after 4 week supplementation
baseline and after 4 week supplementation
change in cholesterol
Tidsramme: baseline and after 4 week supplementation
baseline and after 4 week supplementation

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
change in vascular function
Tidsramme: baseline and after 4-week supplementation
by pulse wave analysis (PWA)
baseline and after 4-week supplementation
change in ALAT/ASAT
Tidsramme: baseline and after 4 week supplementation
baseline and after 4 week supplementation
Urinary metabolites
Tidsramme: after 4 week supplementation
after 4 week supplementation
adipose tissue gene expression
Tidsramme: after 4 week supplementation
by qpcr
after 4 week supplementation
change in markers of inflammation
Tidsramme: baseline and after 4 week of supplementation
by PBMC genexpression and plasma cytokines
baseline and after 4 week of supplementation

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Lydia A Afman, PhD, Wageningen University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. september 2013

Primær fullføring (Faktiske)

1. februar 2014

Studiet fullført (Faktiske)

1. februar 2014

Datoer for studieregistrering

Først innsendt

9. desember 2013

Først innsendt som oppfylte QC-kriteriene

14. februar 2014

Først lagt ut (Anslag)

17. februar 2014

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

17. februar 2014

Siste oppdatering sendt inn som oppfylte QC-kriteriene

14. februar 2014

Sist bekreftet

1. februar 2014

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • NL44919.081.13

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på herbal supplement

Abonnere